Agios Pharmaceuticals Priced, Nasdaq: AGIO
Biotech developing metabolic treatments for cancer and rare genetic diseases.
Industry: Health Care
First Day Return: +73.8%
AGIO
Biotech developing metabolic treatments for cancer and rare genetic diseases.
| IPO Data | |
|---|---|
| IPO Date | 07/23/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $106 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2007 |
| Employees at IPO | 85 |
| Website www.agios.com | |
IPO News for Agios Pharmaceuticals
Agios Pharmaceuticals (AGIO) Performance
